NLM Digital Collections

Search

Start Over Subjects Non-alcoholic Fatty Liver Disease -- drug therapy ✖Remove constraint Subjects: Non-alcoholic Fatty Liver Disease -- drug therapy Publication Year 2022 to 2024 ✖Remove constraint Publication Year: <span class="from" data-blrl-begin="2022">2022</span> to <span class="to" data-blrl-end="2024">2024</span>

1. Technical specifications for submitting clinical trial data sets for treatment of noncirrhotic nonalcoholic steatohepatitis (NASH)

Publication:
[Silver Spring, MD] : Center for Drug Evaluation and Research, January 2022
Subject(s):
Clinical Trials as Topic
Non-alcoholic Fatty Liver Disease -- drug therapy
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

2. Technical specifications for submitting clinical trial data sets for treatment of noncirrhotic nonalcoholic steatohepatitis (NASH)

Publication:
[Silver Spring, MD] : Center for Drug Evaluation and Research, January 2022
Subject(s):
Clinical Trials as Topic
Non-alcoholic Fatty Liver Disease -- drug therapy
United States
United States. Department of Health and Human Services
United States. Food and Drug Administration

3. Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH): final evidence report

Author(s):
Tice, Jeffrey A., author
Fahim, Shahariar Mohammed, author
Richardson, Marina, author
Herce-Hagiwara, Belen, author
Chu, Janet N., author
Pearson, Steven D., author
Rind, David M., author
Suh, Kangho, author
Carlson, Josh, author
Dickerson, Ronald, author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, May 25, 2023
Subject(s):
Chenodeoxycholic Acid -- analogs & derivatives
Liver Cirrhosis -- drug therapy
Non-alcoholic Fatty Liver Disease -- drug therapy
Pyridazines
Uracil -- analogs & derivatives
United States